Report Tools

Pfizer Inc: Re-entry to the OTC healthcare market

Published: April 2013 · Publisher: MarketLine
Pfizer, Inc. was originally founded as fine chemicals business. Following a series of product developments and M&A deals the company is now present in 180 countries around the world, and its portfolio includes human and animal biologic ...
Report Type Case Studies
Language English
Format Electronic (PDF)
Pages17
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6149
Price € 369,00
Options
  • Description
  • Table of Contents
  • Ask a Question
Introduction

Pfizer, Inc. was originally founded as fine chemicals business. Following a series of product developments and M&A deals the company is now present in 180 countries around the world, and its portfolio includes human and animal biologic, small molecule medicines, vaccines, nutritional and consumer products.

Features and benefits

* The publisher's Case Studies describe topics such as innovative products, business models, and significant company acquisitions.
* Fact-based and presented in an accessible style, they explain the rationale of commercial decisions and illustrate wider market and economic trends.

Highlights

In 2006, Pfizer sold its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion. This division of the business included the company’s OTC healthcare products and represented a departure from this market.
Pfizer Chairman and CEO Hank McKinnell described the decision to sell the Consumer Healthcare division as being an “important step to create value for our shareholders while transforming our company”. He went on to describe how the strategy of the company had changed, with the plan being to focus on the core pharmaceutical business.
Following its departure from OTC Healthcare with the sale of its Consumer Healthcare division in 2006, just 3 years later Pfizer re-entered the market with its acquisition of Wyeth. The main reason for this shift back towards OTC healthcare has been the so-called “patent cliff”.

Your key questions answered

* How did Pfizer grow and diversify its business?
* Why did Pfizer sell its Consumer Healthcare division in 2006?
* Why did the company re-enter the OTC market?
* What share the OTC market did Pfizer hold before it sold the Consumer Healthcare division?
* What share the OTC market did Pfizer hold following its acquisition of Wyeth in 2009?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
OVERVIEW
Catalyst
Summary
PFIZER GREW INTO A LARGE DIVERSIFIED BUSINESS
Pfizer was transformed from a fine chemicals company into a pharmaceuticals company
A series of mergers and acquisitions (M&A) has helped the company to grow and diversify
Pfizer acquired Warner–Lambert in 2000
Pfizer merged with Pharmacia in 2003
PFIZER SOLD ITS CONSUMER HEALTHCARE DIVISION IN 2006
Pfizer changed its strategy following a loss in revenues
PFIZER ACQUIRED WYETH IN 2009
Pfizer’s acquisition of Wyeth represented a return to the OTC healthcare market
The OTC healthcare market is growing steadily
Mature pharmaceutical markets have been hindered by the “patent cliff”
PFIZER HAS REGAINED A SIGNIFICANT SHARE OF THE OTC HEALTHCARE MARKET
Pfizer’s Consumer Healthcare business has continued to expand
CONCLUSIONS
Pfizer plans to streamline the business
APPENDIX
Sources
Further Reading
Ask the analyst
About the publisher
Disclaimer
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.